New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 20, 2014
06:33 EDTONCYOncolytics Biotech announces positive data from Resolysin clinical trial
Oncolytics Biotech announced that an abstract detailing early results from translational study looking at the intravenous administration of REOLYSIN to patients with primary or metastatic brain tumors is now available on the ASCO Annual Meeting abstract website. The conference is being held from May 30th to June 3rd Chicago, Illinois. The abstract, titled "Oncolytic wild-type reovirus infection in brain tumors following intravenous administration in patients," contends that intravenous delivery to brain tumors would be easier, cheaper and more acceptable to patients than intralesional administration.
News For ONCY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2015
06:34 EDTONCYOncolytics to present survival data from lung cancer candidate reolysin
Subscribe for More Information
August 26, 2015
06:33 EDTONCYOncolytics completes enrollment in Phase II lung cancer study of Reolysin
Subscribe for More Information
06:32 EDTONCYOncolytics completes enrollment in Reolysin Phase II study
Oncolytics Biotech announced that enrollment has been completed in a randomized Phase II study of Reolysin in patients with previously treated advanced or metastatic non-small cell lung cancer, or NSCLC. The trial is being sponsored and conducted by the NCIC Clinical Trials Group, or NCIC CTG, at Queen's University in Kingston, Ontario. The primary objective of the trial is to evaluate the effect of Reolysin in combination with standard salvage chemotherapy on the progression free survival of patients with advanced or metastatic non-small cell lung cancer. The secondary objectives are to determine the tolerability and toxicity of the therapeutic combination; to investigate additional potential measures of efficacy, including progression rates at three months, objective response rate and overall survival; and to explore potential molecular factors predictive of response. Although accrual is complete, patient follow-up will continue until planned analyses have been conducted.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use